Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 1
1994 2
1997 1
2000 1
2007 2
2008 2
2009 1
2010 1
2011 3
2012 2
2013 3
2014 2
2015 1
2016 3
2019 1
2020 1
2022 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, Lend K, Hørslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljoså MK, Brodin E, Lindegaard H, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group. Østergaard M, et al. Ann Rheum Dis. 2023 Oct;82(10):1286-1295. doi: 10.1136/ard-2023-224116. Epub 2023 Jul 9. Ann Rheum Dis. 2023. PMID: 37423647 Clinical Trial.
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Hetland ML, et al. BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. BMJ. 2020. PMID: 33268527 Free PMC article. Clinical Trial.
Advances in the treatment of rheumatoid arthritis.
Vivar N, Van Vollenhoven RF. Vivar N, et al. F1000Prime Rep. 2014 May 6;6:31. doi: 10.12703/P6-31. eCollection 2014. F1000Prime Rep. 2014. PMID: 24860653 Free PMC article. Review.
Identification of early risk factors for anti-citrullinated-protein-antibody positive rheumatoid arthritis-a prospective cohort study.
Cîrciumaru A, Kisten Y, Hansson M, Mathsson-Alm L, Joshua V, Wähämaa H, Loberg Haarhaus M, Lindqvist J, Padyukov L, Catrina SB, Fei G, Vivar N, Rezaei H, Af Klint E, Antovic A, Réthi B, Catrina AI, Hensvold A. Cîrciumaru A, et al. Among authors: vivar n. Rheumatology (Oxford). 2024 Nov 1;63(11):3164-3171. doi: 10.1093/rheumatology/keae146. Rheumatology (Oxford). 2024. PMID: 38457608 Free PMC article.
Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis.
Yoosuf N, Maciejewski M, Ziemek D, Jelinsky SA, Folkersen L, Müller M, Sahlström P, Vivar N, Catrina A, Berg L, Klareskog L, Padyukov L, Brynedal B. Yoosuf N, et al. Among authors: vivar n. Rheumatology (Oxford). 2022 Apr 11;61(4):1680-1689. doi: 10.1093/rheumatology/keab521. Rheumatology (Oxford). 2022. PMID: 34175943 Free PMC article.
Malignant salivary gland tumors in Quito, Ecuador.
Pacheco-Ojeda L, Domeisen H, Narvaez M, Tixi R, Vivar N. Pacheco-Ojeda L, et al. Among authors: vivar n. ORL J Otorhinolaryngol Relat Spec. 2000 Nov-Dec;62(6):296-302. doi: 10.1159/000027772. ORL J Otorhinolaryngol Relat Spec. 2000. PMID: 11054011 Review.
Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation.
Hughes FM Jr, Vivar NP, Kennis JG, Pratt-Thomas JD, Lowe DW, Shaner BE, Nietert PJ, Spruill LS, Purves JT. Hughes FM Jr, et al. Among authors: vivar np. Am J Physiol Renal Physiol. 2014 Feb 1;306(3):F299-308. doi: 10.1152/ajprenal.00297.2013. Epub 2013 Nov 27. Am J Physiol Renal Physiol. 2014. PMID: 24285499 Free PMC article.
Dendritic cell reprogramming by endogenously produced lactic acid.
Nasi A, Fekete T, Krishnamurthy A, Snowden S, Rajnavölgyi E, Catrina AI, Wheelock CE, Vivar N, Rethi B. Nasi A, et al. Among authors: vivar n. J Immunol. 2013 Sep 15;191(6):3090-9. doi: 10.4049/jimmunol.1300772. Epub 2013 Aug 16. J Immunol. 2013. PMID: 23956421
29 results